Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mereo Biopharma Group Plc ADR (NQ: MREO )

3.920 +0.040 (+1.03%)
Streaming Delayed Price Updated: 1:14 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mereo Biopharma Group Plc ADR

< Previous 1 2 Next >
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Present at the Jefferies Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
From Mereo BioPharma Group plc
Via GlobeNewswire
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan
From Rubric Capital Management LP
Via Business Wire
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.